NCYT.L
HoldSecond WindNovacyt S.A. · Healthcare · France · $42M · Avg Vol: $44K/d
Second Wind: Cheap and rising again, but the business does not yet earn the optimism.
ABOUT NOVACYT S.A.
Read
Novacyt S.A. is an international specialist in clinical diagnostics, developing and manufacturing a comprehensive range of molecular and protein detection technologies. The company gained global prominence during the COVID-19 pandemic with its PCR testing kits and has since diversified into broader infectious disease and oncology diagnostics. It operates as a highly agile diagnostics provider, leveraging its global distribution network and strong R&D pipeline to capture market share in clinical and molecular testing.
FINANCIAL SUMMARY (GBP)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 21.0M | 10.6M | 19.6M | 20.0M | -1.6% | 20.0M | 26.4M | 30.1M | 22.6% |
| EPS (GBp) | -14.00 | -36.00 | -40.00 | -59.00 | -32.40 | — | -32.92 | — | — | — |
| Shares | — | 70.6M | 70.6M | 70.6M | 70.6M | 0.0% | 72.5M | — | — | — |
| Debt | — | 0.9M | 13.7M | 11.9M | 10.4M | 128.8% | 10.4M | — | — | — |
| Equity | — | 115.2M | 87.2M | 47.9M | 23.4M | -41.2% | — | — | — | — |
| Op CF | — | -13.7M | -22.4M | -9.1M | -9.0M | — | -9.2M | — | — | — |
| Inv CF | — | -0.6M | -14.0M | -1.9M | -0.2M | — | — | — | — | — |
| Fin CF | — | -0.5M | -3.1M | -1.7M | -1.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NCYT.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NCYT.L | Novacyt S.A.(you) | $42M | 54 | Hold |
| GBT.PA | Guerbet SA | $112M | 59 | Hold |
| ALTHE.PA | Theraclion SA | $57M | 20 | Sell |
| ALERS.PA | Eurobio Scientific Société anonyme | $233M | 69 | Buy |
| ALMDT.PA | Median Technologies SA | $253M | 12 | Strong Sell |
| ALGAE.PA | Fermentalg SA | $64M | 21 | Sell |
| ALTHX.PA | THX Pharma Société Anonyme | $71M | 9 | Strong Sell |
| AB.PA | AB Science S.A. | $81M | 7 | Strong Sell |
| OSE.PA | OSE Immunotherapeutics SA | $89M | 4 | Strong Sell |
| ALCJ.PA | Crossject Société Anonyme | $115M | 7 | Strong Sell |
Peer medians: ROE -33.6% · P/E 22.9x · Gross margin 73.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.